STAT

Opinion: Lost lives and long odds: Inside STAT’s decision to take on Purdue

STAT pursued unsealing secret Purdue Pharma documents on OxyContin marketing, even though our lawyers told us the odds of winning were against us and the case would be costly.

Last month, I got an email from a dear old friend from Kentucky with devastating news. Her daughter Kathryn had died of an opioid overdose. I was stunned, though perhaps I shouldn’t have been. I knew she had long struggled with addiction: A talented artist and writer, she was prescribed an opioid for wrist pain at 19, and that’s all it took. Eventually, she began using heroin, and now she had overdosed on fentanyl. It’s the same tragic path tens of thousands of other young Americans have traveled.

Kathryn’s mother had a request for me. Could I help her find addresses for members of the Sackler family, who founded and still control the opioid maker Purdue

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.
STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks